CAPLIPOINT: H1 growth and CSU momentum underpin investment-led expansion, with near-term U.S. volatility

H1 revenue rose 18.2%, with cash reserves funding expansion and acquisitions. CSU sales are gaining traction, while U.S. line upgrades and the B2C shift may create near-term volatility; management expects stronger returns as investments mature.

Based on Caplin Point Laboratories Limited [CAPLIPOINT] Q2 26/27 Audio Transcript — Nov. 12 2026